Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-848-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.20 million
Profitability
Miscellaneous
Employees249
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
How were Dynavax Technologies' earnings last quarter?
Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.04. The biopharmaceutical company had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.43 million. Dynavax Technologies had a negative net margin of 1,938.27% and a negative return on equity of 139.00%. Dynavax Technologies's revenue was up 18471.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.45) earnings per share. View Dynavax Technologies' Earnings History.
When is Dynavax Technologies' next earnings date?
What price target have analysts set for DVAX?
4 Wall Street analysts have issued 1-year price targets for Dynavax Technologies' shares. Their forecasts range from $25.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $27.00 in the next twelve months. This suggests a possible upside of 234.2% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.
What is the consensus analysts' recommendation for Dynavax Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.
Has Dynavax Technologies been receiving favorable news coverage?
Headlines about DVAX stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Dynavax Technologies' key competitors?
Some companies that are related to Dynavax Technologies include The Medicines (MDCO), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), AnaptysBio (ANAB), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Mallinckrodt (MNK), Endo International (ENDP), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Allakos (ALLK), Xencor (XNCR), Puma Biotechnology (PBYI) and Myovant Sciences (MYOV).
What other stocks do shareholders of Dynavax Technologies own?
Who are Dynavax Technologies' key executives?
Dynavax Technologies' management team includes the folowing people:
- Mr. Eddie Gray, CEO & Director (Age 60)
- Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
- Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
- Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
- Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)
Who are Dynavax Technologies' major shareholders?
Dynavax Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.59%), Eagle Asset Management Inc. (3.74%), D. E. Shaw & Co. Inc. (3.66%), FMR LLC (3.28%), Northern Trust Corp (1.24%) and Geode Capital Management LLC (1.04%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.
Which institutional investors are selling Dynavax Technologies stock?
DVAX stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc., Hikari Power Ltd, Jane Street Group LLC, MetLife Investment Advisors LLC, Northern Trust Corp, Paloma Partners Management Co, Patriot Financial Group Insurance Agency LLC and Raymond James & Associates. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.
Which institutional investors are buying Dynavax Technologies stock?
DVAX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Macquarie Group Ltd., Royce & Associates LP, D. E. Shaw & Co. Inc., Edmond DE Rothschild Holding S.A., Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Dynavax Technologies.
How do I buy shares of Dynavax Technologies?
Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dynavax Technologies' stock price today?
One share of DVAX stock can currently be purchased for approximately $8.08.
How big of a company is Dynavax Technologies?
Dynavax Technologies has a market capitalization of $517.12 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.
What is Dynavax Technologies' official website?
How can I contact Dynavax Technologies?
Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]
MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
